Kazu Okuma

Summary

Publications

  1. Tezuka K, Okuma K, Kuramitsu M, Matsuoka S, Tanaka R, Tanaka Y, et al. Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor. J Virol. 2018;92: pubmed publisher
  2. Hiyoshi M, Okuma K, Tateyama S, Takizawa K, Saito M, Kuramitsu M, et al. Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo. Retrovirology. 2015;12:73 pubmed publisher
    ..TARC-PE38 robustly controls HTLV-1 infection by eliminating infected cells in both a CCR4- and furin-dependent manner, indicating the excellent therapeutic potential of TARC-PE38. ..
  3. Okuma K, Fukagawa K, Kohma T, Takahama Y, Hamaguchi Y, Ito M, et al. A recombinant vesicular stomatitis virus encoding CCR5-tropic HIV-1 receptors targets HIV-1-infected cells and controls HIV-1 infection. Microbes Infect. 2017;19:277-287 pubmed publisher
    ..Taken together, our findings indicate that a cytolytic rVSV that targets and eliminates R5 HIV-1-infected cells potentially has therapeutic value for controlling R5 HIV-1 infection. ..